ZYTIGA plus prednisone provides overall survival benefit in men with early and less aggressive mCRPC
14
Apr
Janssen-Cilag International NV today announced that data from a post-hoc analysis of the Phase 3 COU-AA-302 trial showed that ZYTIGA? (abiraterone acetate) plus prednisone provided an 11.8 months overall survival (OS) benefit (53.6 months vs 41.8 months; HR = 0.61 … Read More »